已收盘 05-08 16:00:00 美东时间
-0.570
-4.73%
As previously reported, on March 13, 2026, Silvaco Group, Inc. (the "Company") entered into an Open Market Sale Agreement℠ (the "Sales Agreement") with Jefferies LLC (the "Sales Agent"), pursuant to which the Company may
05-09 05:23
Silvaco Group (NASDAQ:SVCO) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.03) by 33.33 percent. This is a 75 percent increase over losses of $(0.08) per share from the
05-08 04:23
Shares software companies are trading higher following Q1 financial results by ...
05-02 01:12
Silvaco Group, Inc. (NASDAQ:SVCO) ("Silvaco" or the "Company"), a provider of TCAD, EDA software, and SIP solutions that enable innovative semiconductor design and digital twin modeling through AI software and
03-30 21:04
Gainers BitFuFu (NASDAQ:FUFU) stock increased by 17.3% to $1.83 during Friday'...
03-21 05:05
The information technology sector is showing signs of overbought stocks which could be a warning for traders who value momentum, according to RSI.
03-20 20:41
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Silvaco业绩会实录,以下是公司财务业绩回顾摘要: ## 1. 财务业绩 **Q4 2025财务表现:** - **总营收**:1,830万美元,超出指导区间高端 - **总预订量**:1,830万美元,达到指导区间高端 - **GAAP毛利率**:83.3% - **Non-GAAP毛利率**:85.6%,超出指导预期 - **GAAP运营亏损**:680万美元 - **Non-GAAP运营亏损**:略超100万美元 - **GAAP净亏损**:720万美元,每股亏损0.24美元 - **Non-GAAP净亏损**:80万美元,每股亏损0.
03-17 12:31
今日重点评级关注:HC Wainwright & Co.:维持Altimmune"买入"评级,目标价从12美元升至25美元;BTIG:维持Jade Biosciences"买入"评级,目标价从28美元升至39美元
03-17 11:45
Silvaco Group (SVCO) hits $5.28 after Q4 beat. Check the latest analyst price targets from Needham and TD Cowen and key support levels.
03-16 22:28
今日重点评级关注:Piper Sandler:维持Allogene疗法"超配"评级,目标价从7美元升至8美元;B. Riley证券:维持Oncology Institute"买入"评级,目标价从6美元升至8美元
03-16 18:19